Theravance Biopharma (NASDAQ: TBPH) announced the initiation of a Phase 2b study of velusetrag (TD-5108), an investigational drug for the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE